Inclusion Criteria:

1. Histologically confirmed diagnosis of advanced solid tumor (dose escalation
component) or metastatic melanoma (uveal or cutaneous) (dose escalation and MTD
expansion components).

2. ASS (argininosuccinate synthetase) deficient tumor.

3. Unresectable disease or patient refused surgery.

4. Progressive disease if treated with chemotherapy, radiotherapy, surgery or
immuno-therapy.

5. Measurable disease as assessed by RECIST 1.1 criteria.

6. Age ≥ 18 years.

7. Karnofsky performance status of ≥ 70.

8. Acceptable hematologic and chemistry laboratory values.

Exclusion Criteria:

1. Serious infection.

2. Pregnancy or lactation.

3. Uncontrolled intercurrent illness.

4. Subjects who have had any anticancer treatment prior to entering the study and have
not recovered to baseline (except alopecia).

5. History of seizure disorder not related to underlying cancer.

6. Known HIV positivity (testing not required).

7. Uncontrolled or progressing CNS metastases.